ReviewAIDS (London, England)2012
The design and evaluation of HIV-1 vaccines.
Review in AIDS (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Trial
- Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120.Frontiers in immunology · 2025Article
- Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding.Nature communications · 2024Article
- B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies.Cell host & microbe · 2021Article
- Article
- Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City.PloS one · 2017Article
- Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.Journal of virology · 2016Article
- Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.Journal of virology · 2016Article
- An infectious molecular clone in early infection with HIV-1 subtype CRF01_AE strains: construction and biological properties.Molecular biology reports · 2015Article
- Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition.Journal of virology · 2014Article
- Article
- Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- HIV-1 vaccines: challenges and new perspectives.Human vaccines & immunotherapeutics · 2014Review
- Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques.Retrovirology · 2013Article
- Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects.Journal of virology · 2013Article
- New clinical trial designs for HIV vaccine evaluation.Current opinion in HIV and AIDS · 2013Review
- Translational research insights from completed HIV vaccine efficacy trials.Journal of acquired immune deficiency syndromes (1999) · 2013Review
- Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primates.Current opinion in HIV and AIDS · 2013Review
- A global approach to HIV-1 vaccine development.Immunological reviews · 2013Review
- Human dendritic cell subsets in vaccination.Current opinion in immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
There is renewed optimism that the goal of developing a highly effective AIDS vaccine is attainable. The HIV-1 vaccine field has seen its first trial of a vaccine candidate that prevents infection. Although modest in efficacy, this finding, along with the recent discovery that the human immune system can produce broadly neutralizing antibodies capable of inhibiting greater than 90% of circulating viruses, provides a guide for the rational design of vaccines and protection by passive immunization. Together, these findings will help shape the next generation of HIV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.